HIPEC FOR
COLORECTAL CANCER
Colorectal cancer is the most common CRS-HIPEC indication globally — with decades of evidence supporting curative-intent surgery for selected patients with peritoneal metastases, achieving median survival of 30–40 months compared to less than 12 months with chemotherapy alone.
analyticsAt a Glance
- check_circle25–35% of CRC patients develop peritoneal metastases — 15,000+ patients annually in Europe alone
- check_circleCRS-HIPEC achieves median OS of 30–40 months in CC-0/1 resected patients vs <12 months with systemic chemotherapy alone
- check_circlePatient selection based on PCI ≤20, absence of unresectable extra-abdominal disease, and acceptable performance status
- check_circleAccessible at specialist CRS-HIPEC centres in China and India via CancerFax at significantly lower cost than Western programmes
Colorectal Peritoneal Metastases: The Clinical Challenge
Colorectal cancer spreads to the peritoneum in 25–35% of patients — either synchronously at the time of primary diagnosis or metachronously, months to years after primary resection. Until the 1990s, peritoneal spread was considered a terminal manifestation of systemic failure, and patients were offered palliative chemotherapy with expected survival of 5–12 months.
“Paul Sugarbaker's insight — that peritoneal metastases from CRC represent locoregional disease that can be treated like locoregional disease — changed the prognosis for tens of thousands of patients who would otherwise have had no curative option.”
Why Peritoneal CRC Is Different from Liver or Lung Metastases
Liver metastases are reached efficiently by systemic IV chemotherapy through the portal circulation. Peritoneal deposits are behind the peritoneal-plasma barrier — systemic chemotherapy concentrations in the peritoneal fluid are 10–20× lower than in the bloodstream. HIPEC bypasses this barrier completely, delivering chemotherapy directly into the peritoneal cavity at concentrations 10–1,000× higher than achievable systemically.
The Role of Complete Cytoreduction
HIPEC chemotherapy penetrates only 1–3 mm into tissue — it cannot sterilise deposits larger than that. Complete cytoreduction (CC-0/1) reduces all deposits to below this penetration depth, allowing HIPEC to address residual microscopic disease that the surgeon cannot physically see or remove. This is why CRS and HIPEC are inseparable: neither is adequate alone.
Clinical Evidence: Key Trial and Registry Data
The following data represent the strongest published evidence supporting CRS-HIPEC for colorectal peritoneal metastases.
Verwaal et al. — First RCT of CRS-HIPEC for CRC Peritoneal Metastases (2003, updated 2008)
Source: Verwaal VJ et al., J Clin Oncol. 2003;21(20):3737–3743; Verwaal et al. 2008 update
- Median OS: CRS-HIPEC arm22.3 mo
- Median OS: systemic chemo arm12.6 mo
- 5-year OS: CRS-HIPEC arm45%
- 5-year OS: systemic chemo arm13%
Contemporary Series (CC-0/1 Resection, PCI ≤20, Modern Systemic Therapy Era)
PSOGI registry and French multicentre series 2015–2022; CC-0/1 only, PCI ≤20
- Median OS after CC-0 resection40–63 mo
- 5-year OS after CC-0 resection40–51%
- Median OS: systemic chemo alone (matched cohort)14–18 mo
HIPEC Chemotherapy Regimens for Colorectal Cancer
Two principal HIPEC regimens are used for colorectal peritoneal metastases — oxaliplatin-based and mitomycin C-based — with ongoing debate about their relative efficacy following the PRODIGE 7 trial.
| Regimen | Drug and Dose | Temperature | Duration | Key Evidence | Notes |
|---|---|---|---|---|---|
| Oxaliplatin (Elias protocol) | Oxaliplatin 360–460 mg/m² + IV 5-FU/LV systemically during HIPEC | 42–43°C | 30 min | French multicentre data; original Elias protocol | |
| Mitomycin C | MMC 15–35 mg total (or 10 mg/m²) ± Cisplatin | 41–42°C | 90 min | Verwaal RCT; US and Dutch protocols | |
| Bidirectional (COMBIDEX) | IV oxaliplatin + IP mitomycin C during HIPEC | 43°C | 30 min | Goéré et al. Phase II | |
| Irinotecan + Oxaliplatin | IP irinotecan 200 mg/m² + IP oxaliplatin 300 mg/m² | 43°C | 30 min | Investigational — Phase I/II |
Eligibility Criteria for CRS-HIPEC in Colorectal Cancer
The following criteria represent the consensus selection framework used at high-volume PSOGI-affiliated CRS-HIPEC centres.
| Criterion | Favourable for CRS-HIPEC | Less Suitable / Caution |
|---|---|---|
| PCI | ≤20 (strict threshold at most centres); ≤17 for some programmes | >20: higher residual disease rate; >25: generally not offered curative intent |
| Extra-abdominal metastases | Absent or limited resectable liver metastases (≤3) | Unresectable liver metastases, lung metastases, retroperitoneal nodes, bone metastases |
| Histology | Mucinous or moderately differentiated adenocarcinoma | Signet ring cell (≥50%) — very poor prognosis even with CC-0; poorly differentiated carcinoma |
| Prior chemotherapy response | Stable or responding disease after FOLFOX/FOLFIRI ± bevacizumab | Rapidly progressive disease on systemic therapy — suggests aggressive biology |
| Performance status | ECOG 0–1; BSA ≥1.4 m² | ECOG 2: careful case-by-case; ECOG 3–4: not suitable; significant cardiac or pulmonary disease |
| Nutritional status | BMI 18.5–30; serum albumin >3.0 g/dL | Severe malnutrition or cachexia — major complication risk substantially elevated |
| KRAS/BRAF status | Any — does not contraindicate surgery | BRAF V600E: associated with worse prognosis but does not exclude surgery at experienced centres |
Key Clinical Numbers
Contemporary outcome benchmarks for CRS-HIPEC in colorectal peritoneal metastases at high-volume centres.
- 40–51%5-year OS after CC-0 resection (modern series)Contemporary series with PCI ≤20 and CC-0 resection — representing the best-case outcome for optimal candidates.
- PCI ≤20Standard eligibility thresholdThe PCI cut-off used at most high-volume centres for curative-intent CRS-HIPEC; some centres use ≤17 as a stricter criterion.
- <3%30-day operative mortality at high-volume centresOperative mortality below 3% is achievable at centres performing >20 CRS-HIPEC cases per year — substantially higher at low-volume centres.
- 25–35%CRC patients who develop peritoneal metastasesFar more common than most patients realise — making CRS-HIPEC one of the higher-volume surgical oncology procedures at dedicated peritoneal oncology centres.
More from the Peritoneal Oncology Resource Library
Continue exploring peritoneal oncology — from PCI scoring and cytoreductive surgery to other tumour type applications.
Frequently Asked Questions
Common questions from colorectal cancer patients exploring CRS-HIPEC.
About CRS-HIPEC for Colorectal Cancer
The PRODIGE 7 trial showed HIPEC did not improve survival over CRS alone — does this mean HIPEC is not effective?
PRODIGE 7 is an important but contested trial. It randomised patients to CRS alone versus CRS + oxaliplatin HIPEC (30-minute protocol) and found no overall survival benefit for the HIPEC arm. However, critics note significant methodological concerns: the 30-minute oxaliplatin dwell time is shorter than used at most centres (most use 30–90 min with mitomycin C); the trial was powered for a larger OS benefit than was realistic; and subgroup analyses showed possible benefit in patients with PCI 11–15. The international PSOGI consensus still supports CRS-HIPEC for eligible CRC patients — but specifically using mitomycin C protocols for which the Verwaal RCT provides Level 1 evidence. The debate is ongoing; CancerFax can connect you with surgeons who will discuss the current evidence honestly for your specific case.
I have both liver and peritoneal metastases. Can I still have CRS-HIPEC?
Having both liver and peritoneal metastases does not automatically exclude CRS-HIPEC, but it does significantly increase the complexity. At specialist centres, synchronous resection of limited hepatic metastases (1–3 lesions, technically resectable) alongside CRS-HIPEC has been performed — with appropriate patient selection. However, extensive hepatic involvement alongside peritoneal disease substantially increases operative risk and decreases expected survival benefit. A multidisciplinary review including both a peritoneal oncology surgeon and a hepatobiliary surgeon is essential before any decision is made.
How quickly should I seek a CRS-HIPEC evaluation after being diagnosed with peritoneal metastases?
As promptly as possible — ideally within 4–6 weeks of the peritoneal diagnosis. Peritoneal carcinomatosis can progress quickly, and the PCI at the time of surgery is the key determinant of outcome. Patients who were PCI 12 at diagnosis can be PCI 22 six months later after disease progression on chemotherapy. Additionally, some chemotherapy regimens — particularly bevacizumab — require a washout period before surgery, and planning this washout into the treatment timeline requires early specialist input. CancerFax can initiate a specialist review of your imaging within days of contact.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could CRS-HIPEC Treat Your Colorectal Peritoneal Metastases?
CancerFax reviews your PCI, imaging, KRAS/BRAF status, and prior chemotherapy history to assess whether CRS-HIPEC is appropriate — and connects you with specialist peritoneal oncology surgeons in China and India with the volume and expertise this surgery requires.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.